# Junta clínica — PT-pseudo_7bcbfa157137 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_7bcbfa157137",
  "pid": "PT-pseudo_7bcbfa157137",
  "task": 1,
  "psa": 7.4,
  "age": 69,
  "months": 1,
  "pirads": "4",
  "psad": 0.117,
  "psav": 1.55,
  "psap": 5.7,
  "vol": 63.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.83814454,
  "medhx": "Hypertension, Type 2 diabetes",
  "meds": "valsartan, lisinopril, metoprolol, metformin, empagliflozin",
  "notes": "PSA 7.4 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 63 mL. csPCa 0.84.",
  "pmhx": [
    "Hypertension",
    "Type 2 diabetes"
  ],
  "allergies": [],
  "vitals": {
    "weight": "89 kg",
    "height": "186 cm",
    "bmi": "25.7",
    "bp": "124/77 mmHg",
    "hr": "69 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested due to previous biopsy positivity alongside a continuous upward trend in PSA levels."
    },
    {
      "s": "History",
      "t": "This 69-year-old gentleman, married and residing with his partner, has recently stepped down from his role as a postal worker. He abstains from tobacco, walks approximately 45 minutes daily, and consumes around 13 units of alcohol weekly. His medical background includes hypertension and type 2 diabetes, currently regulated by valsartan, lisinopril, metoprolol, metformin, and empagliflozin, with recent cardiology parameters remaining stable. Urinary symptoms are negligible, reflected by an IPSS score of 1. Past surgical history encompasses a knee arthroscopy performed half a decade ago, and he occasionally experiences minor lower back stiffness following extended gardening, neither requiring specialist care. He previously opted out of research trials. Adenocarcinoma was confirmed on his earlier biopsy. He maintains full independence in daily activities and remains in good overall health."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Examination is normal; the prostate exhibits a symmetrically enlarged contour with a smooth, firm texture, devoid of palpable asymmetry or discrete nodules. General assessment shows no abnormalities. Blood pressure registers at 124/77 mmHg, accompanied by a regular cardiac rhythm of 69 bpm. Abdominal palpation yields a soft, non-tender abdomen free of palpable masses or organ enlargement."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [],
  "alcohol": "13 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_7bcbfa157137
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 7.4 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.117 ng/mL²
  - PSA velocity: 1.55 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 63.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83814454 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Type 2 diabetes
  - Problem list / PMHx: Hypertension, Type 2 diabetes
  - Current medication: valsartan, lisinopril, metoprolol, metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.4 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 63 mL. csPCa 0.84.

Vitals: weight 89 kg, height 186 cm, BMI 25.7, BP 124/77 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested due to previous biopsy positivity alongside a continuous upward trend in PSA levels.

History: This 69-year-old gentleman, married and residing with his partner, has recently stepped down from his role as a postal worker. He abstains from tobacco, walks approximately 45 minutes daily, and consumes around 13 units of alcohol weekly. His medical background includes hypertension and type 2 diabetes, currently regulated by valsartan, lisinopril, metoprolol, metformin, and empagliflozin, with recent cardiology parameters remaining stable. Urinary symptoms are negligible, reflected by an IPSS score of 1. Past surgical history encompasses a knee arthroscopy performed half a decade ago, and he occasionally experiences minor lower back stiffness following extended gardening, neither requiring specialist care. He previously opted out of research trials. Adenocarcinoma was confirmed on his earlier biopsy. He maintains full independence in daily activities and remains in good overall health.

Physical examination: DRE: Examination is normal; the prostate exhibits a symmetrically enlarged contour with a smooth, firm texture, devoid of palpable asymmetry or discrete nodules. General assessment shows no abnormalities. Blood pressure registers at 124/77 mmHg, accompanied by a regular cardiac rhythm of 69 bpm. Abdominal palpation yields a soft, non-tender abdomen free of palpable masses or organ enlargement.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Walking 45 min/day; IPSS score: 1/35 (mild LUTS).


Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.12 epistemic (95% band 0.23-0.70); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.75: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  2. distance 0.78: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  3. distance 0.86: PI-RADS 4, PSA 4.5, PSAD 0.07, age 71, DRE Normal -> DEFER (clear). He wrote: "Man on active surveillance. MRI stabile and PSA moderately high."

PRECEDENT: DEFER (weighted vote 0.35 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of no biopsy is not decisive because the guideline makes the decision based on MRI stability and PSA density thresholds, which are variables that the panel variables alone do not fully capture. The precedent cited by Expert-Library shows that the decision was based on the need to determine the initial ISUP grade, which is a factor not fully represented by the current panel variables.

WHAT WE STILL NEED
The panel already contains: age (69), PSA (7.4), PI-RADS (4), PSA density (0.117), prostate volume (63.0 mL), DRE finding (Normal), prior-biopsy status (Positive), months since last PSA (1), and csPCa probability (0.83814454).
The prior-biopsy status is Positive, which requires the registrar to open the previous notes to determine the grade of the prior biopsy and the number and dates of biopsy sessions and whether he is on a surveillance protocol with a confirmatory biopsy due.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the prior biopsy grade and surveillance status documented in the previous notes to guide the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI?
  psa_trend (get_psa_trend) -> What is the serial PSA trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Center: Antoni van Leeuwenhoek | Study: Multiparametric MRI of the Prostate | Date: 28 Jan 2025
Lesion size and zone of the mpMRI: "14 mm hypointense focus within the right peripheral zone at the mid-gland level."

psa_trend
Serial PSA trend (rising, flat, or falling): "rising" (Values: 2.2 ng/mL on Feb 2022, 3.0 ng/mL on Feb 2023, 6.8 ng/mL on Feb 2024, 7.4 ng/mL on Jan 2025)

previous_notes
Grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status: "The transrectal ultrasound-guided biopsy conducted earlier this year returned positive histological results."

laboratory_results
Full laboratory results, including free-PSA fraction and renal function: PSA: "7.4 ng/mL" on "24 Dec 2024"; Free PSA: "2.05 ng/mL" on "24 Dec 2024"; %Free PSA: "28%" on "24 Dec 2024"; eGFR: ">60 mL/min/1.73m2" on "24 Dec 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the necessary information regarding the prior biopsy status.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 4 lesion in the right mid peripheral zone.
PSA trend shows a clear rising trajectory.

Findings that argue AGAINST sampling this patient now:
Prior biopsy status is documented as "Positive" in previous notes.

WHERE THIS LEANS
The findings suggest that the decision hinges entirely on the documented prior biopsy grade and surveillance status, as noted by the experts.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 7.40 ng/mL over 4 points spanning 35 months; velocity +2.00 ng/mL per year; doubling time about 18 months.
PROJECTION at 6 months: 8.8 ng/mL, conformal 95% band 2.5-30.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.12 epistemic (95% band 0.42-0.89), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.47  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.65  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.35  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.58 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have addressed the moderator's questions to the extent that the necessary information was retrieved.

ALIGNMENT WITH THE PANEL
The retrieved findings, specifically the rising PSA trend and the PI-RADS 4 lesion, align with the EXPERT-FUSION's suggestion of BIOPSY, which carried the most weight in the PANEL-PROTOCOL.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? This remains unanswered as the previous notes did not explicitly state the grade.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? This remains unanswered as the previous notes did not explicitly state the surveillance status.

WHAT CARRIES WEIGHT, AND WHY
The prior biopsy status, specifically the documented grade (Q1) and surveillance status (Q2), carries the most weight because the EAU guideline specialist noted that the decision hinges entirely on this information.

MY SUGGESTION TO THE CHAIR
Given that the critical variables regarding the prior biopsy grade and surveillance status were not explicitly retrieved, the panel's decision to BIOPSY, supported by the EXPERT-FUSION, is not fully substantiated by the retrieved evidence. We should defer until these specific details are confirmed.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Although the panel protocol suggested biopsy based on the fusion classifier's support, the decision remains borderline because the critical information regarding the prior biopsy grade and surveillance status was not explicitly retrieved. The rising PSA trend and PI-RADS 4 lesion support further investigation, but the lack of documented prior histological grade prevents a definitive conclusion. Therefore, a biopsy is recommended to establish the necessary baseline for definitive management.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
